Grainge Christopher L, Maltby Steven, Gibson Peter G, Wark Peter A B, McDonald Vanessa M
a Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs , The University of Newcastle , Newcastle , Australia.
b Department of Respiratory and Sleep Medicine , John Hunter Hospital , Newcastle , Australia.
Expert Rev Clin Pharmacol. 2016 Jul;9(7):927-41. doi: 10.1586/17512433.2016.1172208. Epub 2016 Apr 14.
Severe asthma is a complex multifactorial disease that requires specialist multidisciplinary input for optimal clinical outcomes. Following multidimensional assessment for optimisation of current therapy, self-management skills and comorbidities, all patients should be accurately phenotyped. Only after this assessment has been completed should new monoclonal antibody therapies be considered. In this review, we summarise the new antibody approaches targeting identified pathological pathways in severe refractory asthma.
重度哮喘是一种复杂的多因素疾病，需要专科多学科的参与以实现最佳临床疗效。在对当前治疗、自我管理技能和合并症进行多维度评估以优化治疗后，所有患者都应进行准确的表型分析。只有在完成此评估后，才应考虑使用新的单克隆抗体疗法。在本综述中，我们总结了针对重度难治性哮喘中已确定的病理途径的新抗体疗法。
